519 related articles for article (PubMed ID: 29480637)
1. Issues with the surgical treatment of antiresorptive agent-related osteonecrosis of the jaws.
Kagami H; Inoue M; Kobayashi A; Taguchi A; Li X; Yoshizawa M
Oral Dis; 2018 Mar; 24(1-2):52-56. PubMed ID: 29480637
[TBL] [Abstract][Full Text] [Related]
2. Medication-related osteonecrosis of the jaw: Surgical or non-surgical treatment?
Favia G; Tempesta A; Limongelli L; Crincoli V; Maiorano E
Oral Dis; 2018 Mar; 24(1-2):238-242. PubMed ID: 29480596
[TBL] [Abstract][Full Text] [Related]
3. Update MRONJ and perspectives of its treatment.
Voss PJ; Poxleitner P; Schmelzeisen R; Stricker A; Semper-Hogg W
J Stomatol Oral Maxillofac Surg; 2017 Sep; 118(4):232-235. PubMed ID: 28697987
[TBL] [Abstract][Full Text] [Related]
4. The Frequency of Medication-related Osteonecrosis of the Jaw and its Associated Risk Factors.
Dodson TB
Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):509-16. PubMed ID: 26362367
[TBL] [Abstract][Full Text] [Related]
5. Denosumab, an Alternative to Bisphosphonates but also Associated with Osteonecrosis of the Jaw--What is the Risk?
Sidhu HK
Dent Update; 2015 Jun; 42(5):436-8, 440. PubMed ID: 26964445
[TBL] [Abstract][Full Text] [Related]
6. Antiresorptive treatment-associated ONJ.
Eleutherakis-Papaiakovou E; Bamias A
Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 29063702
[TBL] [Abstract][Full Text] [Related]
7. Antiresorptive drug-related osteonecrosis of the jaw.
Uyanne J; Calhoun CC; Le AD
Dent Clin North Am; 2014 Apr; 58(2):369-84. PubMed ID: 24655528
[TBL] [Abstract][Full Text] [Related]
8. Is the conservative non-surgical management of medication-related osteonecrosis of the jaw an appropriate treatment option for early stages? A long-term single-center cohort study.
Ristow O; Rückschloß T; Müller M; Berger M; Kargus S; Pautke C; Engel M; Hoffmann J; Freudlsperger C
J Craniomaxillofac Surg; 2019 Mar; 47(3):491-499. PubMed ID: 30642734
[TBL] [Abstract][Full Text] [Related]
9. Drug-induced osteonecrosis of the jaw: the state of the art.
Fassio A; Bertoldo F; Idolazzi L; Viapiana O; Rossini M; Gatti D
Reumatismo; 2017 May; 69(1):9-15. PubMed ID: 28535616
[TBL] [Abstract][Full Text] [Related]
10. Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ.
Khan AA; Morrison A; Kendler DL; Rizzoli R; Hanley DA; Felsenberg D; McCauley LK; O'Ryan F; Reid IR; Ruggiero SL; Taguchi A; Tetradis S; Watts NB; Brandi ML; Peters E; Guise T; Eastell R; Cheung AM; Morin SN; Masri B; Cooper C; Morgan SL; Obermayer-Pietsch B; Langdahl BL; Dabagh RA; Davison KS; Sándor GK; Josse RG; Bhandari M; El Rabbany M; Pierroz DD; Sulimani R; Saunders DP; Brown JP; Compston J;
J Clin Densitom; 2017; 20(1):8-24. PubMed ID: 27956123
[TBL] [Abstract][Full Text] [Related]
11. [Osteonecrosis of the jaws (ONJ) associated to antiresorptive treatment].
Larsson Wexell C; Kjellman A; Akre O
Lakartidningen; 2018 May; 115():. PubMed ID: 29809272
[TBL] [Abstract][Full Text] [Related]
12. Denosumab-related osteonecrosis of the jaws: successful management with a conservative surgical approach.
de Souza Póvoa RC; Marlierè DA; da Silveira HM; Pires FR
Spec Care Dentist; 2016 Jul; 36(4):231-6. PubMed ID: 26859582
[TBL] [Abstract][Full Text] [Related]
13. [Position paper on medication-related osteonecrosis of the jaw (MRONJ)].
Svejda B; Muschitz Ch; Gruber R; Brandtner Ch; Svejda Ch; Gasser RW; Santler G; Dimai HP
Wien Med Wochenschr; 2016 Feb; 166(1-2):68-74. PubMed ID: 26847441
[TBL] [Abstract][Full Text] [Related]
14. Surgical therapy for medication-related osteonecrosis of the jaw in osteoporotic patients treated with antiresorptive agents.
Hauer L; Jambura J; Hrusak D; Chalupova M; Posta P; Rusnak S; Vyskocil V
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2020 Mar; 164(1):100-107. PubMed ID: 30647474
[TBL] [Abstract][Full Text] [Related]
15. Management of Medication-Related Osteonecrosis of the Jaw.
Williams WB; O'Ryan F
Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):517-25. PubMed ID: 26515735
[TBL] [Abstract][Full Text] [Related]
16. Pathophysiology of Osteonecrosis of the Jaws.
Aghaloo T; Hazboun R; Tetradis S
Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):489-96. PubMed ID: 26412796
[TBL] [Abstract][Full Text] [Related]
17. Medication-related osteonecrosis of the jaw associated with bisphosphonates and denosumab in osteoporosis.
Bagan J; Peydró A; Calvo J; Leopoldo M; Jiménez Y; Bagan L
Oral Dis; 2016 May; 22(4):324-9. PubMed ID: 26818808
[TBL] [Abstract][Full Text] [Related]
18. [Preserving the oral health of patients on antiresorptive drugs].
Tilotta F; Folliguet M; Radoï L
Rev Prat; 2023 Apr; 73(4):421-429. PubMed ID: 37289162
[TBL] [Abstract][Full Text] [Related]
19. Denosumab-related osteonecrosis of the jaw: a case report and management based on pharmacokinetics.
You Tm; Lee KH; Lee SH; Park W
Oral Surg Oral Med Oral Pathol Oral Radiol; 2015 Nov; 120(5):548-53. PubMed ID: 26337218
[TBL] [Abstract][Full Text] [Related]
20. Medication-related osteonecrosis of the jaw: risk factors in patients under biphosphonate versus patients under antiresorptive-antiangiogenic drugs.
Ghidini G; Manfredi M; Giovannacci I; Mergoni G; Sarraj A; Mureddu M; Giunta G; Bonanini M; Meleti M; Vescovi P
Minerva Stomatol; 2017 Aug; 66(4):135-140. PubMed ID: 28497661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
